#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3494	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2385	350.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1444	1444	C	472	C,A	440,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3494	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2385	350.4	0	HET	.	.	.	C207T,A	.	207	207	C	467	467	C	304	C,T,A	163,115,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3494	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2385	350.4	0	HET	.	.	.	C451T,G,A	.	451	451	C	711	711	C	447	C,T,G,A	308,103,4,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6106	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3741	396.9	0	.	n	.	0	T695C	SNP	695	695	T	1129	1129	C	399	C,G,T,A	373,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6106	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3741	396.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2405	2405	C	500	C,T,G,A	473,2,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6106	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3741	396.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2479	2479	A	454	A,T	433,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6106	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3741	396.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3031	3031	C	530	C,A,T	488,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6106	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3741	396.9	0	HET	.	.	.	A1638G,C	.	1638	1638	A	2072	2072	A	458	A,G,C	231,211,1	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	602	folP	855	855	100.0	folP.l6.c4.ctg.1	2098	71.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1355	1357	AGC	95;95;94	A;G;C	91;91;89	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	283	1140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4013	70.0	1	SNP	p	S91F	1	.	.	271	273	TTC	863	865	TTC	60;60;60	T;T;C	54;58;58	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	283	1140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4013	70.0	1	SNP	p	D95G	1	.	.	283	285	GGC	875	877	GGC	61;61;62	G;G;C	60;59;61	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	283	1140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4013	70.0	1	SNP	p	G95N	0	.	.	283	285	GGC	875	877	GGC	61;61;62	G;G;C	60;59;61	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	432	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1814	59.1	1	SNP	p	G45D	0	.	.	133	135	GGC	759	761	GGC	104;104;104	G;G;C	92;91;95	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	286	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1820	38.7	0	.	n	.	0	A197.	DEL	197	197	A	1094	1094	A	85	A	80	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1134	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3474	80.5	1	SNP	p	D86N	0	.	.	256	258	GAC	830	832	GAC	83;83;88	G;A,C;C	68;66,1;74	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1134	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3474	80.5	1	SNP	p	R87I	0	.	.	259	261	CGT	833	835	CGT	90;90;90	C;G;T	79;68;70	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1134	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3474	80.5	1	SNP	p	S87R	1	.	.	259	261	CGT	833	835	CGT	90;90;90	C;G;T	79;68;70	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1134	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3474	80.5	1	SNP	p	R87W	0	.	.	259	261	CGT	833	835	CGT	90;90;90	C;G;T	79;68;70	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1134	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3474	80.5	1	SNP	p	S88P	0	.	.	262	264	TCC	836	838	TCC	90;90;90	T;C;C	77;77;82	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1122	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3254	85.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1927	1929	GGC	93;93;95	G;G;C	80;82;82	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	A311V	0	.	.	931	933	GCC	1382	1384	GCC	108;110;110	G,A;C,T,G;C	101,1;103,1,1;105	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	I312M	1	.	.	934	936	ATG	1385	1387	ATG	110;110;109	A,G;T;G,T,A	104,1;105;102,1,1	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	T316P	0	.	.	946	948	ACC	1397	1399	ACC	112;113;113	A,C;C;C	102,1;107;107	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	V316T	1	.	.	946	948	ACC	1397	1399	ACC	112;113;113	A,C;C;C	102,1;107;107	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1898	1900	ACC	124;124;123	A;C;C	114;105;115	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1952	1954	GCG	113;113;113	G;C;G,A,T	105;97;102,1,1	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1952	1954	GCG	113;113;113	G;C;G,A,T	105;97;102,1,1	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2075	2077	GGT	90;91;90	G;G;T	89;89;89	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2084	2086	AGC	75;74;73	A;G;C	57;63;63	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	924	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2523	88.2	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2102	2104	CCG	60;59;58	C;C,G;G,C,A	52;44,1;47,3,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1126	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3466	79.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1697	1699	CCG	112;112;112	C,G;C,G;G,C	92,1;104,1;86,5	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	646	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2369	67.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	823	823	C	62	C,T	54,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	644	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	2251	70.7	1	SNP	p	G120K	1	.	.	358	360	AAG	942	944	AAG	98;98;99	A,C;A,C;G	93,3;95,1;95	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	644	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	2251	70.7	1	SNP	p	N121D	0	.	.	361	363	AAC	945	947	AAC	100;99;99	A,G,C;A;C,A	94,1,1;94;95,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	644	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	2251	70.7	1	SNP	p	A121N	1	.	.	361	363	AAC	945	947	AAC	100;99;99	A,G,C;A;C,A	94,1,1;94;95,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2164	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	5378	99.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	342	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1663	51.3	1	SNP	p	V57M	1	.	.	169	171	ATG	861	863	ATG	121;121;120	A;T;G	112;115;114	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
